Please assess the completion status of the following clinical trial:

Trial Title: Riluzole to Treat Depression in Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Male or female subjects, 18-70 years of age.~Female subjects of childbearing potential must be using a medically accepted means of contraception.~Each subject must have a level of understanding sufficient to agree to all required tests and examinations.~Each subject must understand the nature of the study and must sign an informed consent document.~Subjects must fulfill the criteria bipolar I or II disorder, current episode depressed without psychotic features as defined in the Diagnostic and Statistical Manual (DSM-IV) based on clinical assessment and confirmed by the Structured Clinical Interview for DSM (SCID-P).~Subjects must have an initial score at Visit 1 and Visit 2 of at least 20 on the MADRS.~Current duration of depressive episode should be at least 4 weeks.~Subjects must have experienced, in the opinion of the investigator, at least one previous major depressive episode as defined in DSM-IV (not including the current major depressive episode).~EXCLUSION CRITERIA:~Presence of psychotic features.~Female subjects who are either pregnant or nursing.~Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.~Subjects with uncorrected hypothyroidism or hyperthyroidism.~Clinically significant abnormal laboratory tests.~Current or past blood dyscrasia.~Documented history of hypersensitivity or intolerance to riluzole.~DSM-IV substance abuse or dependence within the past 90 days. No alcohol or recreational drug use will be permitted during the study.~Treatment with an injectable depot neuroleptic within less than one dosing interval between depot neuroleptic injections prior to visit 2.~Treatment with a reversible monoamine oxidase inhibitor (MAOI), guanethidine, or guanadrel within 1 week or with fluoxetine within 5 weeks prior to Visit 2.~Treatment with any other concomitant medication with primarily central nervous system (CNS) activity, other than specified in Appendix A.~Treatment with clozapine or electroconvulsive therapy (ECT) within 4 weeks prior to Visit 2.~Current diagnosis of schizophrenia or other psychotic disorder as defined in the DSM-IV.~Current Axis I Anxiety Disorder that is clinically significant.~Judged clinically to be at serious suicidal risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Riluzole (Type: EXPERIMENTAL): Riluzole was dispensed either once or twice a day as 50 mg tablets. Riluzole dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo pills resembling 50 mg riluzole tables were dispensed either once or twice a day. Dosing began at 50 mg twice per day by mouth and was increased on a weekly basis by 50 mg, as tolerated, to achieve a dose of 200 mg/day. Dose escalations continued until at least a 50% reduction in depression (MADRS) scores, intolerable side effects, or study completion. Dose was raised on a weekly basis by 50 mg until the dose of 200 mg was achieved unless precluded by an adverse event. If significant side effects occurred, titration was slowed and doses were reduced under double-blind conditions. The maximum permitted dose of riluzole was 200 mg/day. Those subjects not tolerating a dosage of 50 mg/day were removed from the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).